Understanding Pine Bark Extract as an Alternative Treatment (UPBEAT) Study

Trial ID or NCT#



not recruiting iconNOT RECRUITING


The purpose of this study is to investigate the efficacy of Flavangenol® (Toyo Shinyaku, Japan), a pine bark extract, in lowering blood pressure and improving glycemic control and plasma lipoprotein profile.

Official Title

Cardiovascular Effects of Pine Bark Extract

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: Yes
Inclusion Criteria:
  1. - Systolic blood pressure between 125 and 159 mmHg and diastolic blood pressure (DBP) < 100 mmHg - Body mass index (BMI) 25.0-34.9 - Triglycerides (TG) < 450 mg/dL - Low Density Lipoprotein (LDL) < 200 mg/dL - Fasting blood glucose (FBG) < 126 mg/dL
Exclusion Criteria:
  1. - DBP > 95 mmHg - LDL > 170 mg/dL - TG > 300 mg/dL - FBG > 110 mg/dL


Randall Stafford
Randall Stafford
Professor of Medicine (Stanford Center for Research in Disease Prevention)

Contact us to find out if this trial is right for you.


Rebbeca Drieling